WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Servier
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pieris Pharmaceuticals, Inc | January 05, 2017
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced it will host an investor conference call today at 8:30 AM (EST) to discuss its strategic immuno-oncology co-development collaboration with Servier....
World Pharma Today | February 20, 2017
OSE Immunotherapeutics SA announced that the company has entered into a worldwide license option agreement with Servier, an independent international pharmaceutical company, for the development and commercialization of OSE Immunotherapeutics’ Effi-7, an antagonist of the interleukin-7 receptor....
pharmaceutical technology | March 07, 2017
UK-based Vernalis and French pharmaceutical company Servier have entered a new oncology drug discovery collaboration....
Pharma Tech
Servier Group and GNS | August 25, 2022
GNS, the leader in the use of "Digital Twins" and Causal AI & biosimulation technology for biopharmaceutical drug discovery and development, and Servier, a global pharmaceutical group, today announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM). "This collaboration furthers Servier's goal to accelerate its drug discovery and clinical development efforts through AI a...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE